{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:54:06Z","timestamp":1759496046122},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,3,2]],"date-time":"2012-03-02T00:00:00Z","timestamp":1330646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Epicutaneous vaccination has gained increasing interest during the past decade as it offers a safe, needle\u2010free, and patient\u2010friendly alternative to invasive vaccine administrations. Recently, the safety and early efficacy of epicutaneous immunotherapy were also demonstrated in patients with hay fever, as an alternative to conventional subcutaneous allergen\u2010specific immunotherapy (<jats:styled-content style=\"fixed-case\">SCIT<\/jats:styled-content>). One major challenge to epicutaneous vaccination is the barrier function of the <jats:italic>stratum corneum<\/jats:italic>, which must be overcome either by abrasive methods or by hydration. Such barrier function of the <jats:italic>stratum corneum<\/jats:italic> also hampers the use of common adjuvants used to enhance the efficacy of vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a mouse model of allergy, we tested the adjuvant potential of diphenylcyclopropenone (<jats:styled-content style=\"fixed-case\">DCP<\/jats:styled-content>), a strong contact sensitizer, which is currently used for the treatment of a T cell\u2010mediated hair loss disease (<jats:italic>alopezia areata<\/jats:italic>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Diphenylcyclopropenone enhanced antigen\u2010specific <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>g<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>2a antibody responses as well as <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201010 cytokine production after epicutaneous immunization with ovalbumin (OVA). Epicutaneous allergen\u2010specific immunotherapy (<jats:styled-content style=\"fixed-case\">EPIT<\/jats:styled-content>) with OVA and <jats:styled-content style=\"fixed-case\">DCP<\/jats:styled-content> also protected sensitized mice from anaphylaxis and asthma. The protective effect was more robust than that of conventional <jats:styled-content style=\"fixed-case\">SCIT<\/jats:styled-content>, which did not significantly alleviate the symptoms of allergy in the murine models of anaphylaxis and asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This preclinical study confirmed previous clinical data that have demonstrated the potential of the skin as a target for allergen immunotherapy. The study also suggests that epicutaneous immunization or immunotherapy can be improved when an appropriate adjuvant such as <jats:styled-content style=\"fixed-case\">DCP<\/jats:styled-content> is used.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1398-9995.2012.02802.x","type":"journal-article","created":{"date-parts":[[2012,3,3]],"date-time":"2012-03-03T20:41:05Z","timestamp":1330807265000},"page":"638-646","source":"Crossref","is-referenced-by-count":15,"title":["The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy"],"prefix":"10.1111","volume":"67","author":[{"given":"S.","family":"von Moos","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"},{"name":"Clinical Trials Center University of Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Waeckerle\u2010Men","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mohanan","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Senti","sequence":"additional","affiliation":[{"name":"Clinical Trials Center University of Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"H\u00e4ffner","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. M.","family":"K\u00fcndig","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60839-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00239-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03430.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.019"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.036"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115884"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2182"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0019-2805.2001.01357.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1934"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/377287"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12395722"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1978.01640230003001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535076"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6346"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2455"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2000.043002095.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2006.01.009"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.001045"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1905"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2009.00884.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.04.004"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02652.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912817107"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090199"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.11.010"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2762"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/379346a0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.2848"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.2.9801014"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9229-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2001.04399.x"},{"key":"e_1_2_8_33_1","article-title":"Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata \u2013 a large retrospective study on 142 patients with a self\u2010controlled design","author":"Ohlmeier MC","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1991"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0292-4"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2009.04.004"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2012.02802.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2012.02802.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:07:17Z","timestamp":1698718037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2012.02802.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1398-9995.2012.02802.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02802.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,2]]}}}